Gastroenterology Billing Services Update: What ColoSense Medicare Coverage Means for Your Revenue Cycle in 2026

Gastroenterology practices are navigating revenue cycle changes on multiple fronts in 2026. 

The 2026 Physician Fee Schedule Final Rule brought reimbursement adjustments that gastroenterology has had to absorb across both facility and non-facility settings. Now, a coverage update adds to the billing complexity: CMS has approved ColoSense, a stool-RNA test developed by Geneoscopy, within its National Coverage Determination for colorectal cancer screening. Medicare beneficiaries now have a third stool-based option alongside existing tests – and gastroenterology billing services teams have another code to build claim logic around.

Revenue cycle leaders in gastroenterology practices should review this change to ensure they are maximizing revenue performance and avoiding billing inefficiencies before ColoSense claim volume arrives. 

Colon cancer screening claims split into two tracks. Preventive screenings, billed under HCPCS G0121 for average-risk patients or G0105 for high-risk, carry zero patient cost-share. The moment a polyp is removed or a biopsy is taken, the claim moves to the diagnostic track, and coinsurance applies.

That split now operates under a tighter 2026 fee schedule. The 2026 Physician Fee Schedule Final Rule applied a -2.5% efficiency adjustment to work RVUs across most non-time-based procedural and diagnostic services [1]. For gastroenterology, the impact varies by setting: facility-based procedures drop 10% while non-facility settings climbs 6%. CMS estimates the cut touches about 7,000 physician services. This is almost 95% of what physicians bill Medicare.

The PFS adjustment raises the cost of each billing error. When base reimbursement is lower, the same coding mistake on the same procedure recovers less on appeal than it would have eighteen months ago. For gastroenterology medical billing teams managing high screening volumes, that margin matters.

CMS added Geneoscopy's ColoSense to its National Coverage Determination for colorectal cancer screening, opening Medicare reimbursement to the first FDA-approved high-sensitivity stool-RNA test [2]. Geneoscopy positions this as a solution to one of the most commonly cited barriers to stool-based screening: the need to handle the sample during collection. ColoSense requires only three steps, with no stool scraping required.

In average-risk patients, ColoSense identifies 93% of colorectal cancers and flags advanced adenomas in 45% of cases, with stage I cancer detection at 100% in the trial's small sample. Both NCCN and ACS guidelines now list ColoSense as a preferred option on a three-year testing interval for adults 45 to 85, the same age range CMS already covers for stool-based screening more broadly.

CMS frames the updated coverage policy as a forward-looking structure designed to absorb future RNA-based tests without requiring a fresh rule-making cycle each time a new assay clears FDA review. For billing teams, that framing is meaningful: a framework built for future coverage means ColoSense will not be the last new code in this category.

Geneoscopy's partnership with Labcorp will widen distribution quickly, which means gastroenterology billing services providers across the country will see ColoSense claims sooner rather than later. Practices that wait for clear coding direction before billing the test risk a backlog once volume hits. Practices that build claim logic and documentation requirements ahead of time can avoid this scramble entirely. It's the same precision gastroenterology medical billing has needed since CMS started layering screening options on top of each other.

For revenue cycle leaders, a newly covered test is a slow cash flow risk waiting to happen. Every code or test that lacks a settled billing pathway adds friction between the date of service and the date of payment. This friction builds straight into an AR backlog. Billing inefficiencies like this rarely show up clearly. They usually show up as a string of small claim corrections that eat staff time and stretch payment timelines. 

Practices running gastroenterology billing in-house often lack the bandwidth to monitor coverage updates, payer bulletins, and code changes across every service line simultaneously. This is a key advantage of outsourced gastroenterology billing services. A dedicated team can build claim rules for a test like ColoSense before it lands in the queue, instead of reacting once claims start bouncing back.

Cologuard remains on the CMS coverage list alongside ColoSense. Effective January 1, 2016, HCPCS code G0464 was discontinued and replaced by permanent CPT code 81528 ($508.87) for billing the Cologuard multi-target stool DNA test. 

ColoSense is assigned Proprietary Laboratory Analyses (PLA) code 0421U ($508.87), specific to the ColoSense™ test manufactured by Geneoscopy Inc. Medicare covers ColoSense once every three years for average-risk patients aged 45 to 85 – those with no personal or family history of colorectal cancer, adenomatous polyps, or inflammatory bowel disease. The applicable diagnosis codes are Z12.11 (encounter for screening for malignant neoplasm of colon) and Z12.12 (encounter for screening for malignant neoplasm of rectum).

One practical billing note: neither CPT 81528 nor PLA code 0421U requires modifier 33 (Preventive Service) or KX attached to the stool test claim itself. These are inherently preventive screening codes. The KX modifier applies to the colonoscopy claim when a colonoscopy follows a positive non-invasive stool test result – it does not go on the stool test code. Importantly, ColoSense (0421U) cannot be billed if the beneficiary has received Cologuard within the same three-year period, and vice versa.

For revenue cycle leaders comparing gastroenterology billing companies, a key differentiator is whether the team behind the claims catches edge cases – like the three-year mutual exclusivity between ColoSense and Cologuard – before they turn into denials.

As gastroenterology billing continues to change with each coverage update and fee schedule adjustment, practice leaders should look beyond reactive billing fixes and build proactive revenue cycle infrastructure.

The ColoSense coverage addition is not an isolated event. It is one more layer in a screening landscape that now includes FOBT, FIT, Cologuard, ColoSense, and a blood-based biomarker test – each with different codes, different coverage criteria, different frequency rules, and different payer-specific requirements. A billing team that cannot track all of these simultaneously creates revenue leakage that looks like small corrections and adds up to significant AR exposure.

3Gen Consulting specializes in helping gastroenterology revenue cycle leaders navigate exactly these challenges. Our team monitors coverage updates, builds payer-specific claim logic before new tests hit volume, and ensures your billing infrastructure adapts to CMS changes before they create backlogs.

Ready to future-proof your gastroenterology billing? Connect with 3Gen's gastroenterology billing specialists.